ORN Study: Curative Treatment of Osteoradionecrosis (ORN) With Hybrid Bone Substitution

NCT ID: NCT01147315

Last Updated: 2018-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-18

Study Completion Date

2016-11-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the study is the cure of osteoradionecrosis (ORN) at 12 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mandible Osteoradionecrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hybrid bone substitution

Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow

Group Type EXPERIMENTAL

Hybrid bone substitution

Intervention Type PROCEDURE

The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hybrid bone substitution

The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (between 18 and 75 years) affiliated with an appropriate social security system, diagnosed as suffering from symptomatic ORN, radiologically confirmed, for which surgery is indicated
* Presence maximum of 2 outbreaks of ORN
* Oncological remission of the original tumor site for 1 year and for 3 years if the ORN is in the contact or close to the initial tumoral site
* ECOG performance status 0, 1 or 2
* ORN symptomatic accessible to the conservation of at least one cortical mandibular basilar
* Signed informed consent

Exclusion Criteria

* Oncological treatment
* Haematologic background
* Current bone necrosis consecutive or concurrent to taking bisphosphonates
* Extension of ORN does not allow the retention of a mandibular rod (bicortical form)
* Presence of fracture complicating ORN
* Bisphosphonates during the last year
* Contraindications to the removal of iliac or sternum bone marrow
* Contraindication for general anesthesia
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nantes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Olivier Malard, Pr

Role: PRINCIPAL_INVESTIGATOR

Nantes University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nantes University Hospital

Nantes, , France

Site Status

Rennes University Hospital

Rennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BRD/08/10-H

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

GBR and Autogenous Bone Chips
NCT03946020 COMPLETED NA